Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LY2606368 Clear all
Completed Phase 1 Interventional

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

NCT04023669
View directory record Official record
Conditions
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
Interventions
Prexasertib, Cyclophosphamide, Gemcitabine, filgrastim, peg-filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 24 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

NCT03057145
View directory record Official record
Conditions
Solid Tumor
Interventions
Prexasertib, Olaparib
Drug
Lead sponsor
Geoffrey Shapiro, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 5, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

NCT06597565
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Gemcitabine, ACR-368
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 5, 2026, 5:46 PM EDT
Terminated Phase 1 Interventional

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

NCT03735446
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Prexasertib, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

NCT02735980
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Prexasertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
14
States / cities
Fayetteville, Arkansas • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

NCT04095221
View directory record Official record
Conditions
Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma
Interventions
Prexasertib, Irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Months and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 5, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

NCT02203513
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Prostate Cancer
Interventions
LY2606368
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study in Participants With Advanced Cancer

NCT01115790
View directory record Official record
Conditions
Advanced Cancer, Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Lung Squamous Cell Carcinoma Stage IV, Anal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung
Interventions
Prexasertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

NCT02555644
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Prexasertib, Cisplatin, Cetuximab, Intensity Modulated Radiation Therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

NCT03414047
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Prexasertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Vallejo, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

NCT02873975
View directory record Official record
Conditions
Advanced Cancers
Interventions
LY2606368
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

NCT02860780
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
Interventions
prexasertib, ralimetinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 5, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296
View directory record Official record
Conditions
Endometrial Adenocarcinoma
Interventions
ACR-368, Gemcitabine, OncoSignature
Drug · Diagnostic Test
Lead sponsor
Acrivon Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
69
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

NCT03495323
View directory record Official record
Conditions
Cancer
Interventions
LY3300054, Prexasertib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

NCT02124148
View directory record Official record
Conditions
Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
Interventions
Prexasertib, Cisplatin, Cetuximab, G-CSF, Pemetrexed, Fluorouracil, LY3023414, Leucovorin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT02649764
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions
Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Prexasertib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

NCT04032080
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Drug 1: LY3023414; Drug 2: Prexasertib
Combination Product
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 5, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Results available

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT02808650
View directory record Official record
Conditions
Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
Interventions
Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 5, 2026, 5:46 PM EDT